Tuesday, December 6, 2016

How much does Lyme disease cost the United States?


Clin Ther. 1998 Sep-Oct;20(5):993-1008; discussion 992.

A cost-of-illness study of Lyme disease in the United States.

Maes E1Lecomte PRay N.

Author information

Erratum in

Clin Ther 1999 Feb;21(2):430.


Lyme disease produces a diverse clinical picture that can include serious and potentially debilitating cardiac, neurologic, joint, and skin involvement. It is characterized in three stages--early localized (stage I), early disseminated (stage II), and late disseminated (stage III)--and medical management is highly dependent on the stage at which the patient presents and the physician's awareness of available treatment options. This study was conducted to establish the medical and economic burden of Lyme disease in the overall US population, which included determining its endemicity in high-risk states and counties, describing current treatment patterns, measuring direct and indirect costs, and defining the cost burden by age group (<18 years and > or =18 years of age). Medical, epidemiologic, and economic data were collected, and an algorithm was developed representing the natural course of Lyme disease and the progress of health states over time following medical intervention. Using an annual mean incidence of 4.73 cases of Lyme disease per 100,000 population in the decision analysis model yielded an expected national expenditure of $2.5 billion (1996 dollars) over 5 years for therapeutic interventions to prevent 55,626 cases of Lyme disease sequelae. This estimate included both direct medical and indirect costs. However, there is evidence of considerable variation in incidence within states. Our findings support development of vaccination strategies for specific target groups.


I found some additional data from the study…these costs were based on 1996 values

The treatment costs for early disseminated disease accounted for 36% of the total direct costs and 64% spent of antibiotic treatments as well as treatment of side effects.


With the costs of late disseminated disease, the values were reversed, 

roughly 2/3rds spent on treatment of the manifestations.


Early disseminated disease cost from: 

$731/per patient/per year for arthritis to 

$3,445/patient/year for cardiac sequelae


Costs for late disseminated:

Musculoskeletal complications $2740/patient/year and 

cardiac complications came to $8270/patient/year 

Saturday, October 15, 2016

Probiotics- Brands Recommended?

Here's part of a thread among doctors about their use of probiotics. Favorite brands, etc. Read from bottom up. 


The Bacillus Subtilis Story:




"For many years afterwards, cultures of Bacillus subtilis were sold worldwide as a medicinal product (sold in the U.S. and Mexico, for example, under the brand name Bacti-Subtil) rapidly becoming the world's leading treatment for dysentery and other intestinal problems. Unfortunately for Americans, this popular bacterial supplement that cures intestinal infections began losing favor in the late 1950's and 1960's, upon the advent of synthetic antibiotics which were heavily touted by the giant pharmaceutical companies as "wonder drugs," even though they cost five times as much as Bacti-Subtil, and took three times longer to accomplish the same results."


Read more:




Probiotic containing Bacillus subtilis: Bio-Identical SBO Probiotics Cosortia



Sent: Thursday, October 13, 2016 1:20:08 AM
Subject: Probiotics- Brands Recommended?

Thought a good conversation on probiotics would be helpful since there are so many on the market today and so many opinions about them.  Do you have a preference and why or why not?

Thursday, October 6, 2016

Wednesday, October 5, 2016

Taipei, Oct. 4 (CNA) A woman has been infected with Lyme disease

Woman confirmed to be infected with Lyme disease

Taipei, Oct. 4 (CNA) A woman has been infected with Lyme disease after getting bitten by a tick in the United States, the Centers for Disease Control reported Tuesday.

The CDC said that the patient is a 60-year-Taiwanese woman who lives in Massachusetts with her family.

She developed numbness on the right side of her face and rashes on her limbs Sept. 11 and sought medical treatment in the U.S. She returned to Taiwan Sept. 14 and sought medical treatment Sept. 19 after her symptoms did not improve.

The CDC said that during the Lyme disease incubation period (Aug. 11-Sept. 8), the woman had contact with wild deer, which are the tick's normal host.

Taiwan has had two confirmed Lyme disease cases so far this year, both imported, one from Sweden and the most recent one from the U.S.

The CDC said that there have been 12 confirmed Lyme cases in Taiwan since 2007, all imported.

Lyme disease is an infectious disease caused by bacteria of the Borrelia type. The most common sign of infection is an expanding area of redness, known as erythema migrans, that begins at the site of a tick bite about a week after it has occurred.

The rash is typically neither itchy nor painful. Approximately between 25 and 30 percent of infected people do not develop a rash.

Other early symptoms may include fever, headache and fatigue. If left untreated, symptoms can include loss of the ability to move one or both sides of the face, joint pain, severe headaches with neck stiffness, and heart palpitations, among others. Months to years later, repeat episodes of joint pain and swelling may occur. 

(By Chen Wei-ting and Lilian Wu)

Thursday, September 22, 2016

Lyme disease is subject of new documentary.

Lyme disease is subject of new documentary at New Jersey Film Festival 

Monday, August 29, 2016

Low-Dose Naltrexone for Lyme treatment

I have mentioned this before in my blog, but saw an email with some links in it today so thought it's high time for me to re-post something here about it. 

Naltrexone, a cancer drug, is used in low doses for treating inflammation.

This one from Dr. Mercola:

Low-Dose Naltrexone (LDN): One of the RARE Drugs that Actually Helps Your Body to Heal Itself

This from the Clinical Rheumatology (2014)

The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain

And this site apparently run by David Gluck, MD of NYC.


Thursday, August 25, 2016

Tuesday, August 23, 2016

Letter by Dorothy Leland rebuttal to Daily Republic news article on Lyme

Dorothy wrote an excellent article, and I'm very glad she refuted Scott Anderson. I tried multiple times to post a comment, but the link does not respond.

— Virginia

Check it out!


Write a response!

You probably didn't see the article that inspired her to write it. Its title is 

Long-term antibiotics not helpful in treating Lyme disease
One of the things the author states is a common myth, since research says up to half the patients continue to have chronic symptoms, not "a minority."

He wrote: "There is a minority of patients, however, who are diagnosed with chronic Lyme disease," 

Daily Republic published it in June and it had only 2 comments.


It was good of them to give Dorothy this opportunity.

Now go and comment so the paper knows we care.


Phyllis Mervine,   CaliforniaLyme    www.LymeDisease.org

Friday, August 19, 2016

Stevia Kills Lyme Disease Pathogen Better Than Antibiotics (Preclinical Study) | GreenMedInfo | Blog Entry

Posted on:

Lyme disease is exceedingly difficult to treat, due to its well-known shape-shifting (pleomorphic) abilities, with conventional antibiotics often failing to produce a long-term cure. Could the commonly used natural plant Stevia provide a safer, and more effective means to combat this increasingly prevalent infection?

A promising new preclinical study has revealed that whole stevia leaf extract possesses exceptional antibiotic activity against the exceedingly difficult to treat pathogen Borrelia Burgdorferi known to cause Lyme disease. The study found...

Read here:

Gut Microbes and the Brain: Paradigm Shift in Neuroscience


The discovery of the size and complexity of the human microbiome has resulted in an ongoing reevaluation of many concepts of health and disease, including diseases affecting the CNS. A growing body of preclinical literature has demonstrated bidirectional signaling between the brain and the gut microbiome, involving multiple neurocrine and endocrine signaling mechanisms. While psychological and physical stressors can affect the composition and metabolic activity of the gut microbiota, experimental changes to the gut microbiome can affect emotional behavior and related brain systems. These findings have resulted in speculation that alterations in the gut microbiome may play a pathophysiological role in human brain diseases, including autism spectrum disorder, anxiety, depression, and chronic pain. Ongoing large-scale population-based studies of the gut….

See the study: